ArticleItalian journal of pediatrics2025
Family costs for pediatric hospitalized respiratory syncytial virus lower respiratory tract infections: an Italian multicenter study.
Article in Italian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease, particularly in young children. It represents a significant cause of morbidity and mortality worldwide, as well as a substantial cost driver in cases requiring hospitalization. The aim of the study was to generate data on the direct and indirect costs borne by families of children hospitalized with RSV-associated acute lower respiratory tract infection (ALRTI). MATERIAL AND
methodsInpatient children aged 24 months of age or below affected by ALRTI were enrolled at nine Italian pediatric hospitals. The study was conducted between November and March of 2022–2024, covering two consecutive RSV seasons in Italy. Direct and indirect costs incurred by families were collected through questionnaires completed by the parents at admission (T0) and again after 7 days (T1).
resultsA total of 296 patients were enrolled during the study period and divided into two groups according to nasal swab results: 225 RSV-positive (76%) and 71 RSV-negative (24%). Family finances were reported to be affected by direct costs in 79% of the RSV+ group and 63.1% of the RSV-group. Direct costs were similar at T0 (€ 52.5 ± 94.6 in RSV+ group and € 53.5 ± 171.4 in RSV- group), but higher at T1 in the RSV+ group (€ 53.8 ± 126.6 vs € 32.3 ± 64.4). Regarding indirect costs, a greater proportion of parents in the RSV-positive group reported taking additional paid leave from work at T1 (41.8% vs 25.3%; p-value = 0.0426) as well as more unpaid leave (13.7% vs 7%). DISCUSSION: This study highlights the substantial economic burden of RSV-related hospitalizations from the household perspective, encompassing both direct out-of-pocket expenses and indirect costs due to work absenteeism across two consecutive epidemic seasons. By documenting the real-life financial impact of RSV on families, our findings provide an important parent-centered perspective, support a more comprehensive evaluation of the RSV burden and underscore the need for broad preventive measures against the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.